Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

F0260000

Fluphenazine decanoate

European Pharmacopoeia (EP) Reference Standard

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C32H44F3N3O2S
Número CAS:
5002-47-1
Peso molecular:
591.77
Número CE:
225-672-4
Número MDL:
MFCD00798504
Código UNSPSC:
41116107
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

fluphenazine

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

cadeia de caracteres SMILES

FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCCN4CCN(CC4)CCOC(=O)CCCCCCCCC

InChI

1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

chave InChI

VIQCGTZFEYDQMR-UHFFFAOYSA-N

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Fluphenazine decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Y0000009

Fluphenazine enantate, European Pharmacopoeia (EP) Reference Standard

Y0000298

Fluphenazine octanoate, European Pharmacopoeia (EP) Reference Standard

Y0000299

Fluphenazine sulfoxide, European Pharmacopoeia (EP) Reference Standard

Y0000708

Fluphenazine impurity mixture, European Pharmacopoeia (EP) Reference Standard

F0280000

Fluphenazine dihydrochloride, European Pharmacopoeia (EP) Reference Standard

1282004

Fluphenazine hydrochloride, United States Pharmacopeia (USP) Reference Standard

1280803

Fluphenazine decanoate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

1281001

Fluphenazine enanthate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1792

Fluphenazine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP167

Fluphenazine hydrochloride, British Pharmacopoeia (BP) Reference Standard

1282026

Fluphenazine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palavra indicadora

Danger

Frases de perigo

H300,H361

Classificações de perigo

Acute Tox. 2 Oral - Repr. 2

Código de classe de armazenamento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Janice Charles et al.
Australian family physician, 35(3), 88-89 (2006-03-10)
The BEACH program, a continuous national study of general practice activity in Australia, gives us an overview of consultations involving the management of psychoses. In this analysis we have included schizophrenia, affective disorders/bipolar, organic psychoses, and senile psychoses, with undefined
Rajaprabhakaran Rajarethinam et al.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 10(4 Pt 2), 416-419 (2009-06-06)
Aripiprazole, a partial dopamine agonist has been reported to help reduce symptoms of tardive dyskinesia (TD). In a prospective, open label study of a series of cases, we examined the effectiveness of aripiprazole in reducing TD symptoms. Six clinically stable
Mis-deca-n identity?
Elizabeth A S Giugni et al.
The Medical journal of Australia, 187(6), 370-370 (2007-09-19)
Zana Stanković et al.
Psychiatria Danubina, 20(1), 42-52 (2008-04-01)
To compare patient's attitudes, demographic, clinical characteristics, psychopathology, insight and type of antipsychotic therapy in compliant and non-compliant outpatients with schizophrenia; to explore correlations between patient's attitudes and related variables. A sample of 44 outpatients of both genders (> 60
Martin Turner et al.
International clinical psychopharmacology, 19(4), 241-249 (2004-06-18)
Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. Participants in this open-label, multicentre, 12-week trial had received flupenthixol decanoate, fluphenazine decanoate, haloperidol decanoate, or
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica